Hero

USPTO Decides to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

1

USPTO Decides to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2THINK Trial in Belgium

2

Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2THINK Trial in Belgium

Developing breakthrough pioneering therapies for life-threatening diseases

3

Developing breakthrough pioneering therapies for life-threatening diseases

Directing a weaponized attack on cancer with the NKR-T cell immunotherapy

4

Directing a weaponized attack on cancer with the NKR-T cell immunotherapy

About Celyad

Driven by a passion to invent

Celyad is a clinical-stage biopharmaceutical company focused on the discovery and development of breakthrough pioneering cell-based therapies for life-threatening diseases.

More info about Celyad

Latest News

Celyad Announces USPTO Decision to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Celyad Announces USPTO Decision to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Celyad Announces Registration of the first patient in the Belgian THINK trial

Celyad Announces Registration of the first patient in the Belgian THINK trial

Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2 THINK Trial in Belgium

Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2 THINK Trial in Belgium

Discover all news

Carousel

Social Feed

THINK includes 3 dose levels, the patients will receive 3 successive administrations, two weeks apart, of autologous CAR-T NKR-2 cells.

1 week ago

THINK includes 3 dose levels, the patients will receive 3 successive administrations, two weeks apart, of autologous CAR-T NKR-2 cells.

Analyst says @CelyadSA takes lead in CAR-T for solid tumors as THINK trial gets underway https://t.co/IJlIWJaDts #FierceBiotech

1 week ago

Analyst says @CelyadSA takes lead in CAR-T for solid tumors as THINK trial gets underway https://t.co/IJlIWJaDts #FierceBiotech

Analyst says Celyad takes lead in CAR-T for solid tumors as THINK trial gets underway

1 week ago

Analyst says Celyad takes lead in CAR-T for solid tumors as THINK trial gets underway

#Cancer: Espoir d'un traitement révolutionnaire @CelyadSA Thank you! @JulesBordet @ULBruxelles @ClinUnivStLuc… https://t.co/d6iSdXHFrj

1 week ago

#Cancer: Espoir d'un traitement révolutionnaire @CelyadSA Thank you! @JulesBordet @ULBruxelles @ClinUnivStLuc… https://t.co/d6iSdXHFrj

THINK includes 3 dose levels, the patients will receive 3 successive administrations, two weeks apart, of autologous CAR-T NKR-2 cells.

1 week ago

THINK includes 3 dose levels, the patients will receive 3 successive administrations, two weeks apart, of autologous CAR-T NKR-2 cells.

Analyst says @CelyadSA takes lead in CAR-T for solid tumors as THINK trial gets underway https://t.co/IJlIWJaDts #FierceBiotech

1 week ago

Analyst says @CelyadSA takes lead in CAR-T for solid tumors as THINK trial gets underway https://t.co/IJlIWJaDts #FierceBiotech

#Cancer: Espoir d'un traitement révolutionnaire @CelyadSA Thank you! @JulesBordet @ULBruxelles @ClinUnivStLuc… https://t.co/d6iSdXHFrj

1 week ago

#Cancer: Espoir d'un traitement révolutionnaire @CelyadSA Thank you! @JulesBordet @ULBruxelles @ClinUnivStLuc… https://t.co/d6iSdXHFrj

RT @ClinUnivStLuc: Notre hôpital teste un nouveau traitement par immunothérapie cellulaire afin de lutter contre 7 types de cancers https:/…

1 week ago

RT @ClinUnivStLuc: Notre hôpital teste un nouveau traitement par immunothérapie cellulaire afin de lutter contre 7 types de cancers https:/…

Analyst says Celyad takes lead in CAR-T for solid tumors as THINK trial gets underway

1 week ago

Analyst says Celyad takes lead in CAR-T for solid tumors as THINK trial gets underway

Cancer : Espoir d'un traitement révolutionnaire. Celyad

1 week ago

Cancer : Espoir d'un traitement révolutionnaire. Celyad

Registration of the First Pancreatic Cancer Patient in its THINK Trial in Belgium

1 week ago

Registration of the First Pancreatic Cancer Patient in its THINK Trial in Belgium

JPM-HealthcareConference-SFO-Jan2017.jpg

1 week ago

JPM-HealthcareConference-SFO-Jan2017.jpg